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Abstract
Adherence to consensus guidelines for cancer care may vary widely across health care settings and 
contribute to differences in cancer outcomes. For some women with breast cancer, omission of 
adjuvant chemotherapy or delays in its initiation may contribute to differences in cancer 
recurrence and mortality. We studied adjuvant chemotherapy use among women with stage II or 
stage III, hormone receptor–negative breast cancer to understand health system and socio-
demographic correlates of under-use and delayed adjuvant chemotherapy. We used Surveillance 
Epidemiology and End Results (SEER)-Medicare linked data to examine the patterns of care for 
6,678 women aged 65 and older diagnosed with stage II or stage III hormone receptor–negative 
breast cancer in 1994–2002, with claims data through 2007. Age-stratified logistic regression was 
employed to examine the potential role of socio-demographic and structural/organizational health 
services characteristics in explaining differences in adjuvant chemotherapy initiation. Overall 
utilization of guideline-recommended adjuvant chemotherapy peaked at 43% in this population. 
Increasing age, higher co-morbidity burden, and low-income status were associated with lower 
odds of chemotherapy initiation within 4 months, whereas having positive lymph nodes, more 
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advanced disease, and being married were associated with higher odds (P < 0.05). Health system–
related structural/organizational characteristics and race/ethnicity offered little explanatory insight. 
Timely initiation of guideline-recommended adjuvant chemotherapy was low, with significant 
variation by age, income, and co-morbidity status. Based on these findings, future studies should 
seek to explore the more nuanced reasons why older women do not receive chemotherapy and why 
delays in care occur.
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Introduction
Health disparities with regard to breast cancer outcomes among elderly, low-income, rural-
dwelling, and minority women are well documented [1, 2]. The extent to which these 
disparities result from differences in quality of cancer treatment is unknown. Barriers to 
delivery of high-quality cancer treatment include poor dissemination systems, provider 
resistance or lack of awareness of new evidence, the fragmented nature of the health care 
financing system, lack of effective monitoring, poor communication, and lack of incentives 
to change practices [3, 4].
Clinical guidelines are intended to help standardize treatment regimens across providers. 
Although awareness of differences in molecular subtypes of breast cancer and development 
of novel therapeutic and diagnostic tools [5–8] have yielded refined clinical guidelines for 
the management of breast cancer, adjuvant chemotherapy has remained the cornerstone of 
systemic therapy for patients with hormone receptor–negative disease since 1990 [9]. Joint 
American Society of Clinical Oncology/National Comprehensive Cancer Network (ASCO/
NCCN) quality measures emphasize the importance of both administration of chemotherapy 
for such patients and initiation of therapy within 4 months of diagnosis [10]. Although 
consensus guidelines for breast cancer have focused on women under the age of 70, 
emerging evidence suggests clear benefits from adjuvant chemotherapy in older populations 
as well [11].
Variation in cancer treatment quality across patients may be related to both patient-level 
socio-demographic and health system-level structural/organizational characteristics. 
Adherence to guidelines and delivery of evidence-based care depends in part on diffusion of 
information across diverse health care organizations and providers [12, 13]. Thus, access to 
and receipt of chemotherapy in a timely fashion may vary based on where a patient receives 
care and corresponding structural/organizational factors of those institutions. It seems 
plausible that differences in structural/organizational factors, such as access to a National 
Cancer Institute (NCI)—designated cancer center, location of initial surgical care, and 
distance to chemotherapy providers, may vary across vulnerable populations that experience 
breast cancer disparities and may in part contribute to these disparities. To date, the degree to 
which these structural and organizational aspects of cancer care affect appropriate 
administration of chemotherapy for breast cancer and subsequent outcomes is unclear.
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Although the interrelated effects of patient and structural/organizational characteristics of 
health services on quality of care have been explored in some diseases [14–18], these 
relationships have been much less systematically and comprehensively studied in breast 
cancer treatment. One study of North Carolina Medicaid beneficiaries showed that poor-
quality breast cancer care was related to older age, living in a more rural county, receiving 
surgery at a smaller hospital, and living in a low-specialist density county [19].
We aimed to contribute to the existing evidence on the quality of breast cancer care in 
vulnerable subpopulations by examining trends in receipt and timing of initiation of adjuvant 
chemotherapy among Medicare-enrolled, stages II–III, hormone receptor–negative patients 
and by determining whether differences in structural/organizational factors, including 
distance to care and institutional affiliations, and select socio-demographic characteristics 
accounted for treatment differences.
Methods
Data source and patient population
The Surveillance, Epidemiology and End Results (SEER)-Medicare dataset was used in the 
current study [20]. We identified all women in the SEER-Medicare dataset with their first or 
only primary breast cancer diagnosed in the years 1994–2002, with claims data through 
2007. We required that patients were (1) continuously enrolled in Medicare parts A and B 
fee-for-service during the one-year period prior to diagnosis and at least one year post-
diagnosis, or until death, whichever occurred first; (2) non-Hispanic white, non-Hispanic 
black, or Hispanic patients (i.e., other groups were excluded because of their small numbers 
and insufficient power to examine racial/ethnic variation in quality of care); (3) 65 years and 
older at diagnosis; (4) stage II or III breast cancer at diagnosis; (5) not diagnosed with breast 
cancer at death or autopsy only, because these patients were not eligible for the outcome of 
interest, treatment, given their time of diagnosis at death; and (6) receiving breast conserving 
surgery or aggressive surgery/mastectomy as the first anti-cancer treatment. We further 
excluded women who received neoadjuvant chemotherapy prior to surgery, had end-stage 
renal disease, or were diagnosed with additional cancer within one year of the index breast 
cancer diagnosis, since care provided for these patients is likely different from the general 
breast cancer patient population. We focused our multivariate analyses on women with 
hormone receptor–negative cancers, defined as tumors not testing positive for estrogen or 
progesterone receptivity. This subgroup of patients represents women who are ineligible for 
endocrine therapy and for whom adjuvant chemotherapy is the cornerstone of systemic 
treatment, conferring a significant survival benefit [10, 21]. We refer to this group as 
“hormone receptor–negative” throughout, but it is important to note that also included in this 
definition are women with borderline or unknown hormone receptor status, since their care 
should be clinically similar in the absence of a positive hormone receptor test result.
Dependent variable
Initiation of any post-operative adjuvant chemotherapy within four months of diagnosis was 
our primary dependent variable. The 4-month time interval provides sufficient time for 
surgery and medical consultation and is consistent with ASCO/NCCN quality metrics [10]. 
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Because women receive chemotherapy from various types of facilities [22], we extracted 
data from inpatient, carrier, outpatient, and durable medical equipment files using codes 
from the Healthcare Common Procedure Classification System (HCPCS), the International 
Statistical Classification of Diseases and Related Health Problems, 9th revision, clinical 
modification (ICD-9-CM), and National Drug Codes (NDC) (Table 1).
Independent variables of interest
Structural/organizational characteristics of oncologic health services included surgical 
facility type/ownership, bed size, teaching status, NCI cancer center designation, and 
American College of Surgeons Oncology Group (ACoSOG) affiliation, each of which was 
available in the SEER-Medicare data. ACoSOG membership is a proxy for organizational 
clinical expertise in the absence of information about Commission on Cancer (CoC) 
accreditation; in general, most ACoSOG hospitals are CoC-accredited. Distance to providers 
(for surgery and nearest chemotherapy provider) was calculated using zip code centroid to 
zip code centroid minimum distance algorithms [23–27]. We created quartiles of distance 
traveled to surgical providers and nearest chemotherapy providers for multivariate models.
Patient-level characteristics included race/ethnicity, age, co-morbidity, low-income status, 
marital status, and clinical factors that influence treatment decisions. We used SEER registry 
definitions of race/ethnicity [28]. Because guidelines for adjuvant chemotherapy differ by 
age, we stratified analyses by age group (65–69 years old versus 70 years and older) and 
included age as a categorical independent variable in the models of women aged 70 years 
and older. Co-morbidities were assessed using the NCI combined index method [29], which 
has been shown to be a better predictor of non-cancer mortality among breast cancer 
survivors than other commonly used co-morbidity measures [29]. We created quartiles of co-
morbidity scores for multivariate models.
We included several covariates previously shown to influence chemotherapy and breast 
cancer treatment decision making, including AJCC stage of disease and histologic grade [30, 
31]; marital status as a measure of social support [32]; neighborhood racial and ethnic 
composition (proportions of white, black, and Hispanic residents within the zip code of 
residence) [33, 34]; zip code-level income and education; year of diagnosis; and low-income 
status (measured by having any State-Buy-In (SBI) months during the study period) [28, 35, 
36]. The SBI variable indicates that the state paid for supplemental insurance through its 
Medicaid program for individuals who met certain low-income requirements and applied for 
the program; thus, because many low-income people do not apply for SBI, it is a specific, 
but not particularly sensitive, measure of low-income status [28].
Statistical analysis
Receipt of adjuvant chemotherapy within four months of diagnosis was examined 
descriptively and modeled using multivariate logistic regression. Bivariate analyses 
compared receipt of chemotherapy and distribution of structural/organizational factors by 
race/ethnicity and age, using chi-squared tests [37]. In building analytic multivariate logistic 
models, tests were employed to determine the most appropriate variable specification (e.g., 
use of the continuous versus categorical forms of co-morbidity index score) for the final 
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analytic models [38, 39]. Corrected Huber-White standard errors were reported for all 
models, and tests for multicollinearity among variables were conducted [39]. A P value 
threshold of 0.05 was considered statistically significant.
Results
We identified 20,898 women with incident breast cancer diagnosed in 1994–2002 who met 
initial inclusion/exclusion criteria (i.e., all criteria except hormone receptor status). As 
shown in Table 2, approximately 8% of women were non-Hispanic black, 4% were 
Hispanic, and 88% were non-Hispanic white. The median age at diagnosis was 76.6 years. 
Overall, 68% were endocrine receptor positive, of whom 98% were estrogen receptor (ER) 
positive and 79% were progesterone receptor (PR) positive; 6,678 women were neither ER 
nor PR positive. Younger women and those with hormone receptor–negative tumors more 
often received chemotherapy.
Structural/organizational characteristics of health services were distributed unequally across 
racial/ethnic sub-populations (Table 3). Hispanic women were treated more often at for-
profit surgical facilities (16% compared to 7% in whites and 8% in blacks; P < 0.001), and 
black women received surgery more often at NCI Comprehensive Cancer Centers (9% 
compared to 2% in white women and 3% in Hispanic women; P < 0.001), ACoSOG-
affiliated facilities (32% compared to 22% in white women and 15% in Hispanic women; P 
< 0.001), and teaching/academic health centers (62% compared to 48% in white women and 
41% in Hispanic women; P < 0.001) (Table 3). Black women were less likely to live in a zip 
code where a chemotherapy facility was available (P < 0.001).
In multivariate models, among women who had hormone receptor–negative tumors, for 
whom adjuvant chemotherapy is guideline-recommended, uptake of adjuvant chemotherapy 
was low overall (43%), even in the latest year for which data were available. Characteristics 
of the surgical facility where women were treated were not predictive of initiation of 
adjuvant chemotherapy within four months of diagnosis (Tables 4, 5). Among women aged 
70 and older (Table 5), increasing distance to a chemotherapy facility and increasing 
distance to the surgical facility were consistently associated with lower odds of adjuvant 
chemotherapy within four months, although the effect was often statistically non-significant.
In general, low-income status was associated with significantly lower odds of chemotherapy 
initiation at four months, despite the fact that everyone in the sample was Medicare-insured 
(OR: 0.49, P < 0.01 in the 65–69 age group; OR: 0.59, P < 0.01 in the 70 and older age 
group). Having positive lymph nodes, being diagnosed as stage III (relative to stage II), 
being married, and being diagnosed in later years were generally associated with 
significantly higher odds of chemotherapy within four months. Among women aged 70 and 
older only (Table 5), increasing age and greater co-morbidity were associated with 
significantly lower odds of chemotherapy initiation at four months (P < 0.01 for both).
Discussion
We examined the association between structural/organizational factors in health care 
delivery, race/ethnicity, and age and the timing of adjuvant chemotherapy among older 
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women with breast cancer and found low overall utilization and significant variation in 
timing of initiation of adjuvant chemotherapy. Although the distribution of structural/
organizational factors varied significantly by racial/ethnic group, this variation did not 
appear to correlate with disparities in chemotherapy utilization. Rather, among hormone 
receptor–negative women, for whom adjuvant chemotherapy with or without trastuzumab is 
the sole systemic therapy option, failure to receive chemotherapy within four months was 
associated with increasing age, earlier year of diagnosis, being unmarried, and lower-income 
status. Overall, it was reassuring that chemotherapy utilization appeared more likely among 
patients with lymph node–positive and high-grade disease and lower among those with 
serious co-morbidity.
Age was strongly associated with receipt of chemotherapy within four months of diagnosis, 
consistent with prior studies [36, 40–42]. Due to insufficient accumulation of clinical trial 
evidence about the effects of adjuvant chemotherapy in older women, clear guidelines were 
lacking for breast cancer patients older than 70 during this period [10]. However, many 
experts have argued that underrepresentation of older women in clinical trials should not 
preclude their receiving potentially life-prolonging breast cancer treatments [43, 44]. 
Moreover, clear evidence now exists indicating benefit from adjuvant chemotherapy within 
this patient subgroup and particularly those with hormone receptor–negative disease [11, 21, 
42, 45, 46]. Our data serve to highlight the need to develop guidelines for older patients with 
breast cancer and provide an important benchmark for further research in this area.
The lack of a racial/ethnic disparity in the current study contrasts with findings of other 
work documenting significant racial/ethnic differences in chemotherapy use for breast 
cancer patients in select geographic regions with mixed insurance status [32, 47], but is in 
line with results from patients in single insurer systems, such as the military health system 
and Medicare [41, 48]. As such, the lack of racial/ethnic effect in the current study may be 
explained by the insured status of the underlying SEER-Medicare sample. Our findings may 
suggest that the structure and organization of health services used by minority groups with 
insurance do not affect receipt of adjuvant chemotherapy; alternatively, features of SEER-
Medicare sampling, problems with measurement of structural/organizational variables, 
and/or omission of unobservable variables could explain this finding. For instance, although 
SEER is one of the largest national cancer registry programs in the world, SEER largely 
samples black and Hispanic cancer patients from specific areas (e.g., many black patients 
live in Detroit and Atlanta) which may not be representative of the experiences of rural-
dwelling black and Hispanic persons in the United States [20]. Our subanalyses comparing 
health system organizational/structural factors by race/ethnicity (Table 3) support this 
premise, as black women in this study were more likely to be treated at larger hospitals, NCI 
Comprehensive Cancer Centers, and academic facilities, which have been associated with 
improved treatment quality and/or health outcomes [18, 49–51] and which are reflective of 
more urban health facilities. Given the low numbers of Hispanic women in our sample, our 
findings may not be representative of their experiences as a whole, regardless of urban/rural 
residence.
Among women aged 70 and older, increasing distance to chemotherapy providers was 
associated with lower odds of receiving adjuvant chemotherapy at various time periods, but 
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this effect was not always statistically significant. If distance to care presents an obstacle to 
elderly women, public health programs focused on providing reliable transportation options 
may benefit women. Given the limitations of using straight-line distances between zip code 
centroids, it is possible that our measures were too imprecise to detect the true effect of 
distance on care delivery. As such, future research should explore in more depth issues 
around geographic access to care as it relates to treatment planning and perceived burden of 
seeking oncology services among older women.
Despite the high predictive power of many variables related to tumor characteristics, co-
morbidities, marital status, and income, we were unable to directly measure intent, treatment 
choice, or other behavioral factors that may have affected receipt of care. The decision to 
pursue or forgo adjuvant chemotherapy for older patients with breast cancer is complex, 
requiring consideration of toxicity, benefits, competing co-morbid conditions, and logistical 
burdens patients may face during treatment. As such, reasons for underuse of adjuvant 
chemotherapy are multifaceted and cannot be completely understood in a retrospective 
observational study of this nature. Nevertheless, older women in good health could benefit 
from chemotherapy [11] and thus may be systematically undertreated and unnecessarily 
missing out on life-sustaining therapy. Moreover, because patients receiving neoadjuvant 
chemotherapy were excluded from this analysis, pre-operative use of chemotherapy is 
unlikely to contribute to the low levels of adjuvant chemotherapy utilization.
This study has several strengths, including its use of a large, population-based cancer 
registry linked with Medicare claims data and longitudinal examination of trends in breast 
cancer care. We have also addressed one important potential source of omitted variable bias
—insurance status—by limiting our study to insured Medicare beneficiaries continuously 
enrolled in parts A and B fee-for-service. Despite controlling for insurance status, however, 
we found significantly lower odds of chemotherapy initiation within four months among 
low-income women, suggesting that low-income women may experience financial barriers 
to care that extend beyond insurance status. Future studies should employ patient interviews 
or focus groups with low-income women comparable to those in this study to elucidate these 
additional barriers; for example, lower-income, older women may be more likely to stay in 
the workforce than more affluent, older women, and workforce participation may conflict 
with keeping chemotherapy appointments.
This study extends our understanding of breast cancer treatment by (1) documenting low 
utilization of adjuvant chemotherapy over time among important patient subpopulations, 
including older, low-income, unmarried women, (2) illustrating substantial variation in 
timeliness of initiation of chemotherapy (which may be related to subsequent health 
outcomes [52]), and (3) showing potential age-related disparities in treatment among healthy 
elderly women with good functional status. Combined with recent data on the likely benefit 
of standard adjuvant chemotherapy in the older breast cancer population [11], it is possible 
that outcomes may be improved for a substantial number of older patients. Future studies 
should seek to explore the more nuanced reasons why older women do not receive 
chemotherapy and to better identify women at risk for under-treatment and delays in care. 
Moreover, older women may need better access to information about risks/benefits of 
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adjuvant chemotherapy and improved access to chemotherapy providers (e.g., through better 
referral processes and transportation to chemotherapy facilities).
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Table 1
Identification of surgery and chemotherapy in Medicare claims
Treatment Primary means of identification
Diagnostic codes ICD-9-CM diagnosis codes: 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9
Other: V10.3
Aggressive surgery ICD-9-CM procedure: 85.41, 85.42, 85.43, 85.44, 85.45, 85.46, 85.47, 85.48
CPT/HCPCS: 19180, 19182, 19200, 19220, 19240, 19260–19272, 19303–19307
Breast conserving surgery ICD-9-CM procedure: 85.20, 85.21, 85.22, 85.23, 85.24, 85.25
CPT/HCPCS: 19120, 19125, 19126, 19160, 19162, 19301, 19302
Chemotherapy ICD-9-CM procedure: 99.25, 285.3, 999.81
CPT/HCPCS: 51720, 96400–96549, 99555, Q008–3Q0085 (oral), C9127, C9415, C9420, C9421, C9431, C8953–
C8955, S9329–S9331, G0355, G0357–G0363, G9021–G9032, J8510, J8520, J8521, J8530–J8999 (oral), J9000–
J9999 (IV)
Revenue Center Code: 0331, 0332, 0335
DRG: 410, 492
Other: V58.1, V58.11, V66.2, V67.2, V87.41, NDC codes
Specific NDC codes that were included in searches are available upon request
CPT current procedural terminology, DRG diagnostic related group, HCPCS health care common procedure classification system, ICD-9-CM 
international statistical classification of diseases and related health problems, 9th revision, clinical modification, NDC national drug code
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Table 3
Distribution of health system structural/organizational factors by race/ethnicity in full sample
Organizational covariates % or mean (SD)
N = 18,462
White
% or mean (SD)
N = 1,596
Black
% or mean (SD)
N = 740
Hispanic
P value (from chi-
square test or t-test)
Surgical facility characteristics
 Type/ownership
  For-profit/private 6.9% 8.4% 15.7% < 0.001
  Non-profit/voluntary 78.5% 77.9% 69.7% < 0.001
  Government 14.5% 13.7% 14.6% 0.682
 NCI Comprehensive Cancer Center 2.3% 9.5% 3.0% < 0.001
 ACoSOG-affiliated 22.3% 32.4% 14.9% < 0.001
 Teaching/academic facility 48.5% 61.6% 41.1% < 0.001
 Rural location 14.0% 4.9% 9.9% < 0.001
 Number of beds 353 (226.2) 465 (259) 302 (219) < 0.001~
< 0.001#
Relational factors/access to care
 Nearest chemotherapy facility (miles) 3.2 (6.2) 1.9 (3.9) 4.2 (10.0) < 0.001~
< 0.001#
 Nearest chemotherapy facility is located in same zip 
code as patient residence
84.9% 80.2% 87.4% < 0.001
 Facility where patient received primary surgery is 
located in same zip code as patient residence
17.5% 14.9% 16.3% 0.027
 Average distance traveled for primary surgery (miles) 15.6 (61.6) 11.5 (50.9) 11.5 (31.8) 0.011~
0.061#
 Average distance traveled to chemotherapy provider, 
among those who received chemotherapy (first incidence 
of use) (miles)
17.5 (55.4) 11.5 (31.4) 13.3 (23.5) 0.029~
0.53#
ACoSOG American College of Surgeons Oncology Group, NCI National Cancer Institute
~
Indicates two-sample t-tests between white and black groups,
#
indicates two-sample t-tests between white and Hispanic groups
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Table 4
Multivariate logistic regression models for breast cancer patients 65–69 years old with non-positive (i.e., 
negative, borderline, or unknown) hormone receptor status
Receipt of adjuvant chemotherapy within 4 months of diagnosis
Variables Odds ratio 95% Confidence interval
Structural/organizational variables
 Surgical facility characteristics
  Non-profit (reference)
  Private/for-profit 1.07 (0.61–1.89)
  Governmental 1.04 (0.66–1.62)
teaching facility 0.86 (0.61–1.22)
  Fewer beds (< median) 1.02 (0.71–1.45)
  NCI Comprehensive cancer center 0.60 (0.27–1.32)
  ACoSOG-affiliated 1.04 (0.70–1.56)
 Distance traveled to surgery (in quartiles)
  Same zip code (reference)
  Surgery distance Q1 1.27 (0.75–2.14)
  Surgery distance Q2 0.88 (0.54–1.43)
  Surgery distance Q3 0.93 (0.56–1.53)
  Surgery distance Q4 1.37 (0.81–2.33)
Distance to nearest chemotherapy provider (in quartiles)
  Same zip code (reference)
  Chemotherapy distance Q1 1.24 (0.69–2.24)
  Chemotherapy distance Q2 1.08 (0.60–1.97)
  Chemotherapy distance Q3 1.14 (0.67–1.93)
  Chemotherapy distance Q4 1.16 (0.65–2.05)
Clinical and patient characteristics
 Non-Hispanic white (reference)
 Non-Hispanic black 0.84 (0.50–1.43)
 Hispanic 1.58 (0.84–2.97)
 NCI Combined Index Co-morbidity score (in quartiles)
  None (score = 0) (reference)
  Co-morbidity Q1 0.95 (0.58–1.56)
  Co-morbidity Q2 1.27 (0.67–2.42)
  Co-morbidity Q3 0.78 (0.41–1.47)
  Co-morbidity Q4 0.32c (0.17–0.60)
 Stage II (reference)
 Stage III 1.93b (1.13–3.30)
 Node-negative (reference)
 Node-positive 4.33c (3.09–6.07)
 Node status missing 1.05 (0.60–1.83)
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Receipt of adjuvant chemotherapy within 4 months of diagnosis
Variables Odds ratio 95% Confidence interval
 Low-income proxy (State-Buy-In) 0.49c (0.33–0.72)
 Married 1.54c (1.12–2.11)
 Diagnosed in 1994 (reference)
 Diagnosed in 1995 1.46 (0.80–2.66)
 Diagnosed in 1996 0.72 (0.37–1.38)
 Diagnosed in 1997 1.16 (0.58–2.32)
 Diagnosed in 1998 1.85a (0.93–3.68)
 Diagnosed in 1999 3.26c (1.55–6.83)
 Diagnosed in 2000 2.41c (1.30–4.45)
 Diagnosed in 2001 2.87c (1.54–5.35)
 Diagnosed in 2002 2.00b (1.08–3.72)
 Observations 1,082
Models also control for grade, unknown hormone receptor status, timing of surgery, and zip code-level socioeconomic characteristics
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Table 5
Multivariate logistic regressions for breast cancer patients 70 years and older with non-positive (i.e., negative, 
borderline, or unknown) hormone receptor statuses
Receipt of adjuvant chemotherapy within 4 months of diagnosis
Variables Odds ratio 95% Confidence interval
Structural/organizational variables
 Surgical facility characteristics
  Non-profit (reference)
  Private/for-profit 1.17 (0.88–1.55)
  Governmental 0.83 (0.66–1.05)
  Teaching facility 0.94 (0.79–1.13)
  Fewer beds ( < median) 1.03 (0.86–1.23)
  NCI Comprehensive Cancer Center 0.84 (0.54–1.31)
  ACoSOG-affiliated 1.07 (0.87–1.31)
 Distance traveled to surgery (in quartiles)
  Same zip code (reference)
  Surgery distance Q1 0.88 (0.68–1.13)
  Surgery distance Q2 0.85 (0.66–1.09)
  Surgery distance Q3 0.86 (0.66–1.11)
  Surgery distance Q4 0.79a (0.61–1.04)
 Distance to nearest chemotherapy provider (in quartiles)
  Same zip code (reference)
  Chemotherapy distance Q1 0.86 (0.64–1.15)
  Chemotherapy distance Q2 0.74b (0.55–1.00)
  Chemotherapy distance Q3 0.8 (0.61–1.05)
  Chemotherapy distance Q4 0.92 (0.69–1.23)
Clinical and patient characteristics
 Non-Hispanic white (reference)
 Non-Hispanic black 1.04 (0.77–1.40)
 Hispanic 1.49a (0.99–2.24)
 Aged 70–74 years (reference)
 Aged 75–79 years 0.45c (0.38–0.54)
 Aged 80–84 years 0.18c (0.15–0.23)
 Aged 85 years and older 0.04c (0.03–0.05)
 NCI combined index co-morbidity score (in quartiles)
  None (score = 0) (reference)
  Co-morbidity Q1 0.92 (0.71–1.19)
  Co-morbidity Q2 0.79 (0.59–1.06)
  Co-morbidity Q3 0.64c (0.49–0.85)
  Co-morbidity Q4 0.59c (0.44–0.77)
 Stage II (reference)
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Receipt of adjuvant chemotherapy within 4 months of diagnosis
Variables Odds ratio 95% Confidence interval
 Stage III 1.50c (1.21–1.86)
 Node-negative (reference)
 Node-positive 4.00c (3.34–4.79)
 Node status missing 1.03 (0.78–1.36)
 Low-income proxy (State-Buy-In) 0.59c (0.48–0.73)
 Married 1.14a (0.98–1.34)
 Diagnosed in 1994 (reference)
 Diagnosed in 1995 1.08 (0.75–1.57)
 Diagnosed in 1996 1.11 (0.76–1.63)
 Diagnosed in 1997 1.53b (1.02–2.28)
 Diagnosed in 1998 1.81c (1.25–2.62)
 Diagnosed in 1999 2.15c (1.45–3.20)
 Diagnosed in 2000 2.66c (1.87–3.77)
 Diagnosed in 2001 2.52c (1.77–3.59)
 Diagnosed in 2002 2.56c (1.80–3.65)
 Observations 4,823
Models also control for grade, unknown hormone receptor status, timing of surgery, and zip code-level socioeconomic characteristics
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